Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy
Clinical trial NCT05456698 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05456698
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-18
- Primary completion
- 2025-11-05
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.